Pune, India, November 2019, MRFR Press Release/- Market Research Future has published a Half-Cooked Research Report on the Global Cardiac Biomarkers Market.
According to MRFR analysis, Cardiac Biomarkers Market is expected to register a CAGR of 16.36% during the forecast period of 2019 to 2025 and accounted for USD 1446.11 Million in 2018.
Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of having these conditions or to help monitor and manage someone with ACS and cardiac ischemia.
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global cardiac biomarkers market. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are expected to be the largest market owing to the high spending by the pharmaceutical industry. The cardiac biomarkers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European cardiac biomarkers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac biomarkers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising affordability for advanced cardiac treatments and increasing disposable incomes, the market in Asia-Pacific is expected to be the fastest-growing. The cardiac biomarkers market in the Middle East & Africa has been divided into the Middle East and Africa.
Cardiac Biomarkers Market Segmentation
The Global Cardiac Biomarkers Market has been segmented based on Type, Location of Testing, and Application.
The market, based on type, has been divided into myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNP) or NT-proBNP and ischemia modified albumin (IMA). Troponins (T and I) is the maximum revenue generating segment due to its high cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death.
The global cardiac biomarkers market has been segmented, on the basis of the location of testing, into point of care testing and laboratory testing. The point of care testing segment is expected to witness the fastest growth due to its increasing popularity in cardiovascular disease diagnostics.
The market, based on application, has been divided into acute coronary syndrome, myocardial infarction, congestive heart failure, atherosclerosis, and others. The acute coronary syndrome held the largest market share in 2018. It is a medical emergency that requires prompt diagnosis and care.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594
Some of the Key Players in the Global Cardiac Biomarkers Market are Abbott Laboratories (US), ACS Biomarker (The Netherlands), BD (Becton, Dickinson and Company) (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson and Johnson (US), Quidel Corporation (US), Randox Laboratories Limited (UK), Siemens AG (Germany), Thermo Fisher Scientific, Inc. (US), Trivitron Healthcare Pvt. Ltd. (India), and Novartis (Switzerland).